Funding of €17m has been awarded to four high-tech health projects involving Galway companies.
It's part of the latest allocations under the Government's Disruptive Technologies Innovation Fund.
The largest allocation of €6.3m is to a Galway-based consortium developing a high-tech implant device in patients with atrial fibrillation.
The project is a joint venture between AuriGen Medical, Integer Holdings, Bryvant, Aran Biomedical and ATU Galway.
A further €6m will support a medtech device delivering targeted therapies for vascular disorders and cancers.
The national consortium behind that project includes Galway firms LaNua Medical and Integer Holdings.
Next, and €2.9m has been allocated to an agri-venture looking to enhance nutrient efficiency and reduce greenhouse gas emission.
It involves University of Galway, and spin-out company GlasPort Bio.
And €2.1m has been awarded to a consortium that includes local firm Fortis Medical Devices Teoranta.
They're developing a high-tech device that aims to enhance or restore mobility functionality in stroke patients.
